Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

1.354 -0.026 (-1.91%)
Streaming Delayed Price Updated: 10:50 AM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
InMed Pharmaceuticals Expands Rare Cannabinoid Product Portfolio to Launch CBT ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
Via Investor Brand Network
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
Via Investor Brand Network
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
Via CannabisNewsWire
Topics Supply Chain
News headline image
InMed Pharmaceuticals' Issues Annual Shareholder Letter ↗
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
4 Penny Stocks Insiders Are Buying ↗
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... 
Via Benzinga
InMed Pharmaceuticals’ (NASDAQ: INM) Issues Annual Shareholder Letter
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook
Via Investor Brand Network
News headline image
InMed Pharmaceuticals to Present at Tribe Public's Webinar Event ↗
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and... 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
Via Investor Brand Network
News headline image
InMed Pharmaceuticals Announces Publication of Article on CBN as Possible Glaucoma Treatment ↗
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Announces Publication of Article on CBN as Possible Glaucoma Treatment
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment
Via Investor Brand Network
News headline image
InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment ↗
InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following... 
Via Benzinga
InMed Pharmaceuticals’ (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment
Via Investor Brand Network
News headline image
InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs ↗
InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio... 
Via Benzinga
Topics Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
Via CannabisNewsWire
Topics Intellectual Property
News headline image
InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update ↗
InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 ↗
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: 
Via Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
Via CannabisNewsWire
News headline image
InMed Pharmaceuticals Announces Participation in Upcoming Cannabis Conference ↗
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis... 
Via Benzinga
Topics Cannabis
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Cannabis Conference
Via Investor Brand Network
Topics Cannabis
News headline image
Welcome to the Party $INM! Competition or Compliment to $SNDL? — Cannabis Daily November 18, 2021 ↗
The Best Daily Overview Of The Cannabis Space South Dakota lawmakers recommend bill to legalize marijuana. New York ban... 
Via Benzinga
Topics Cannabis
News headline image
54 Biggest Movers From Yesterday ↗
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company... 
Via Benzinga
News headline image
44 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.